Pricing Log in Create free account

Silence Therapeutics PLC Sponsored ADR (SLN) vs Urogen Pharma (URGN)

Silence Therapeutics PLC Sponsored ADR and Urogen Pharma are both Biotechnology companies. Silence Therapeutics PLC Sponsored ADR and Urogen Pharma are of similar size ($1.3B and $1.2B). Urogen Pharma grew revenue faster over the last twelve months: 159.3% against −97.0%. Silence Therapeutics PLC Sponsored ADR has the higher net margin (0.00% vs −26.3%) and the higher return on invested capital (0.00% vs 0.00%). Across the 16 metrics below, Urogen Pharma leads on 11 and Silence Therapeutics PLC Sponsored ADR on 5.

Valuation

Metric SLN URGN Biotechnology median
P/E n/m n/m 10.60
P/S 1,110.83 5.01 9.40
P/B 24.23 n/m 2.13
Price to free cash flow n/m n/m 25.18
EV/EBITDA n/m n/m 0.66
EV/Sales 1,025.03 5.41 9.02
Earnings yield (6.49%) (5.32%) (32.88%)
Free cash flow yield (4.54%) (10.53%) (23.13%)

Profitability

Metric SLN URGN Biotechnology median
Gross margin 79.50% 91.41% 68.51%
Operating margin 0.00% (12.36%) 0.00%
Net margin 0.00% (26.27%) 0.00%
Free cash flow margin 0.00% (52.77%) 0.00%
Return on equity (90.41%) 54.65% (51.96%)
Return on assets (44.14%) (28.78%) (46.06%)
Return on invested capital 0.00% 0.00% 0.00%

Growth

Metric SLN URGN Biotechnology median
Revenue growth (TTM) (96.97%) 159.29% 6.76%
EPS growth (last fiscal year) (90.91%) (7.77%) 29.88%
Revenue growth, 5-year CAGR (39.74%) 56.22% 9.75%
Net income growth, 5-year CAGR 0.00% 0.00% 0.00%

Health

Metric SLN URGN Biotechnology median
Debt to equity 0.00 (1.53) 0.00
Current ratio 7.42 3.40 4.97
Net debt to EBITDA 0.94 0.00 1.01

Dividend

Metric SLN URGN Biotechnology median
Dividend yield — — 0.41%
Payout ratio — — —

Size

Metric SLN URGN Biotechnology median
Market cap 1.23b 1.26b 161.82m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack